To further define this receptor, we report results of expression cloning studies from an MCF-7 cell library. We isolated two variants of a seven-transmembrane receptor that were identical to two previously described human calcitonin receptors (hCTR1 and hCTR2). These receptors were characterized by expression in different surrogate host cell systems. Transient expression of hCTR1 in COS cells yielded membranes that bound 125 I-AC512 and 125 I-salmon calcitonin with high affinity, but no high affinity binding was observed with 125
To further define this receptor, we report results of expression cloning studies from an MCF-7 cell library. We isolated two variants of a seven-transmembrane receptor that were identical to two previously described human calcitonin receptors (hCTR1 and hCTR2). These receptors were characterized by expression in different surrogate host cell systems. Transient expression of hCTR1 in COS cells yielded membranes that bound 125 I-AC512 and 125 I-salmon calcitonin with high affinity, but no high affinity binding was observed with I-rAmylin ϭ 8% B max ). In both expression systems, the agonists hCAL and rAmylin were much more potent in displacing their radioligand counterparts than was the antagonist radioligand 125 I-AC512. For example, the pK i value for displacement of 125 I-AC512 by rAmylin was 7.2 in HEK 293 cells but rose to 9.1 when displacing 125 IrAmylin. Finally, hCTR2 was expressed in baculovirus-infected Ti ni cells. In this system, only specific binding to the antagonist 125 I-AC512 and agonist 125 I-hCAL was observed; no binding to 125 I-rAmylin could be detected. These data are discussed in terms of two working hypotheses. The first is that amylin is a weak agonist for hCTR2 and that this receptor is unrelated to the amylin receptor found in this cell line. The second is that hCTR2 couples to different G proteins for calcitonin and amylin function in different cells. At present, these data cannot be used to disprove conclusively either hypothesis.
Amylin is a peptide hormone that is synthesized and secreted from pancreatic ␤ cells. There is evidence that an increase in the cosecretion ratio of amylin to insulin exacerbates insulin tolerance, and in general, there are data to suggest that this peptide may be important in the pathology of type II diabetes (1) (2) (3) (4) (5) . High affinity binding for 125 I-rAmylin has been reported in the rat nucleus accumbens (6 -8) , thus defining an operational and experimentally accessible amylin receptor. Similar high affinity binding of both 125 IrAmylin and an sCAL antagonist analogue radiolabel 125 I-AC512 has been described (9) in human MCF-7 cells. These data raise the possibility that these cells contain a human amylin receptor, and this information would be of value in the study of the role of amylin in human type II diabetes. bovine serum (10%). Cells were grown as a monolayer, fed fresh media every 3 days, and split 1:2 weekly. Transfected COS-7 or HEK 293 cells were also cultured in Eagle's minimal essential medium with nonessential amino acids, sodium pyruvate [1 mM (90%)], and fetal bovine serum (10%). The cells were grown as a monolayer, fed fresh media every 3 days, and split 1:2 weekly.
Membrane preparation. The nucleus accumbens was dissected from the brains of Sprague-Dawley rats (200-250 g) and homogenized (three 15-second bursts) in ice-cold HEPES buffer (20 mM HEPES, pH adjusted to 7.4 with NaOH at 23°). The homogenate was centrifuged at 48,000 ϫ g for 15 min and washed twice by resuspension in fresh buffer. The membrane pellet from the third centrifugation was resuspended in fresh buffer with 0.2 mM PMSF, aliquoted, and stored at Ϫ70°. The MCF-7 cells were harvested at confluency by manual scraping of the tissue culture flasks. The cells then were pelleted by centrifugation at 2000 rpm for 15 min and homogenized as described above.
Cultured cells were harvested at confluency by manual scraping of the tissue culture flasks, then pelleted by centrifugation at 2000 rpm for 15 min, and homogenized (three 15-second bursts) in ice-cold HEPES buffer (20 mM HEPES, pH adjusted to 7.4 with NaOH at 23°). The homogenate was centrifuged at 48,000 ϫ g for 15 min and washed twice through resuspension in fresh buffer. The membrane pellet from the third centrifugation was resuspended in fresh buffer with 0.2 mM PMSF, aliquoted, and stored at Ϫ70°.
Synthesis of AC512. To a solution of the peptide (Ac)LGKLSQELHRLQTY-PRTNTGSNTY(NH 2 ) (128.5 mg, 80% peptide content, 36.4 mol; synthesized using normal solid-phase techniques from Fmoc-protected amino acids and a Rink resin) in 25 mM aqueous NaHCO 3 (30 ml, pH ϳ 8) maintained at 0°we added dropwise a solution of 14.2 mg of cold Bolton-Hunter reagent [3-(3-iodo-4-hydroxyphenyl)-propanoic acid N-hydroxysuccinimide ester] in 8 ml of acetonitrile. The resulting solution was stirred for 2 hr at 0°. An additional 10 mg of the Bolton-Hunter reagent in 5 ml of acetonitrile was added at this point, and the solution was stirred for 1 additional hr at 0°. The reaction was quenched by the addition of sufficient 10% aqueous trifluoroacetic acid to give pH 1.5 and warmed to room temperature. This solution was filtered to remove a small amount of precipitated material. The filtrate was injected onto a Waters (Milford, MA) Delta-Prep HPLC equipped with a radial compression C-18 cartridge (conditions: flow rate, 100 ml/min; solvent A ϭ CH 3 CN, solvent B ϭ 0.1% aqueous trifluoroacetic acid; initial conditions were 73% B; 4 min after the injection a linear gradient was begun, decreasing the percentage of B to 53% over 40 min). The desired product, AC512, eluted at 22.5 min. Lyophilization gave 89.2 mg of AC512 as a white powder. Peptide content was found to be 64.5%. High resolution mass spectrum (electrospray): expected monoisotopic MHϩ 3092.4091, found: 3092.4423. The most likely spot for derivatization of the starting peptide is on the lysine, and AC512 is assigned the structure (Ac)LG(KBH)LSQELHRLQTYPRTNTG-SNTY(NH 2 ) with (KBH) being lysine labeled on the ⑀-amino group with the Bolton-Hunter reagent. The 125 I-labeled material was synthesized at Amersham (Arlington Heights, IL) using the same starting peptide and radioactive Bolton-Hunter reagent. The Amersham 125 I-labeled peptide coeluted with the nonradioactive peptide synthesized as described above.
Receptor binding. Membranes were incubated with 125 I-rAmylin (Bolton Hunter labeled at the amino-terminal lysine; Amersham) or 125 I-AC512 (Bolton Hunter-labeled [Arg18,Asn30,Tyr32]9-32 sCAL, 2000 Ci/mmol; Amersham) in 20 mM HEPES buffer, containing 0.5 mg/ml bacitracin, 0.5 mg/ml bovine serum albumin, and 0.2 mM PMSF (all from Sigma Chemical, St. Louis, MO) plus test ligand or ligands, for 60 min at 23°(samples mixed on a Titer Plate Shaker; Lab-Line Instruments). Nonspecific binding was defined as the radioactivity remaining in the presence of 100 nM sCAL. Incubations were carried out in triplicate tubes and were started by the addition of membrane. Binding was terminated by filtration through glassfiber filters (presoaked 30 min in 0.5% polyethyleneimine), using the Skatron semiautomatic cell harvester. Filters were placed in Sarsted 68.752 51 ϫ 12 mm polypropylene tubes and counted for 1 min in a ␥-counter.
Binding data were analyzed with the Glaxo Wellcome statistical fitting package RADLIG (Glaxo Wellcome Scientific Computing) to simultaneous equations describing total binding (saturable binding according to a logistic equation plus a linear nonspecific binding curve) and a linear nonspecific binding curve. Statistical analyses were used to determine whether data could be fit to a single or double population of binding sites. Saturation analysis yielded a nonlinear least-squares fit to the logistic equation with a half-maximal fitting parameter (the equilibrium dissociation constant of the ligand/receptor complex under ideal conditions, denoted K d ) and a maximal asymptote (denoted B max , providing an estimate of the maximal number of binding sites in fmol/mg of protein). Displacement analysis (radioligand concentrations ϭ 0.3 ϫ K d ; incubations for 90 min) yielded concentrations of nonradioactive ligand that half-maximally displaced a given concentration of radioligand (denoted IC 50 ). This value was used to calculate an estimate of the equilibrium dissociation constant of the nonradioactive ligand/receptor complex (denoted K i ) by correction for the amount of radioactive ligand and the K d value (11) . Complex displacement curves were fit to a two-population model, yielding two apparent affinities and the relative quantities of two apparent sites (or receptor states).
Molecular biology. Standard molecular biology techniques were used (12) . Poly(A) ϩ RNA was isolated using a FastTrack RNA isolation kit (InVitrogen, San Diego, CA). Both strands of the CTR cDNA were sequenced with an ABI394 automatic sequencer with use of the Analysis (Applied Biosystems, Foster City, CA) and Assembly LIGN (Kodak IBI, New Haven, CT) software programs.
Construction of cDNA library. Five micrograms of poly(A) ϩ RNA, isolated from MCF-7 cells, was used to construct a size-selected cDNA library according to the manufacturer's protocol (InVitrogen). Double-stranded, oligo(dT)-primed cDNA was synthesized and ligated to NotI/EcoRI adaptors. Fragments of cDNA of Ͼ1.6 kb were isolated and subsequently ligated into the EcoRI site of expression vector pMT4 (13) . Aliquots of the library were titered by electroporation into Top10 competent cells (Stratagene, La Jolla, CA). Pools of colonies, representing Ϸ1000 independent cDNAs/pool, were scraped from plates and grown for 4-6 hr in 25 ml of LB-ampicillin. Plasmid DNA from each pool was isolated using the Wizard Midiprep DNA purification system (Promega, Madison, WI). Expression cloning. Pools of cDNA were transfected into COS-7 cells and analyzed for their ability to bind 125 I-sCAL or 125 I-AC512 in transient transfection assays. Initial experiments were done with 125 I-sCAL; however, in view of the nearly irreversible kinetics of this radioligand, later experiments were done with 125 I-AC512. On day 0, 3-4 ϫ 10 5 COS-7 cells/well were plated onto six-well dishes. On day 1, cells were transfected with 1 g of DNA from each pool per well using lipofectamine (GIBCO BRL, Gaithersburg, MD) according to the manufacturer's instructions. Cells were assayed 48 hr after transfection by binding analysis (see below). After screening 0.6 ϫ 10 6 clones, four pools that bound 125 I-ligand were identified. One pool was progressively subdivided into smaller pools until a single positive clone was obtained.
Generation of stable cell lines. On day 0, HEK 293 cells were plated at a concentration of 10 6 cells/100-mm dish. On day 1, cells were cotransfected with clone 77/pMT4 or clone 134/pMTR with pRSV/neo at a 10:1 ratio, respectively, according to the calcium phosphate method (Promega). On day 3, transfected cells were selected using G418-supplemented media at a concentration of 600 g/ml. After a 2-week selection period, several colonies from each transfection were selected and expanded. 6 cells/ml were infected at a multiplicity of infection of 2 plaque-forming units/cell and were harvested 48 hr after infection. Cells pellets were washed once with phosphate-buffered saline and then frozen until assayed.
Microphysiometry. This technique is based on the principle that the metabolism of cells is tightly linked to hydrogen ion output. A thin disk of cells is cultured over a pH detector and perfused with medium. Although perfusion takes place, the pH registered by the detector is constant. At regular intervals, the perfusion is stopped and the hydrogen ion allowed to accumulate in the chamber. The resulting decrease in pH with time is measured as a rate; this rate is proportional to the metabolic state of the cell. The overall cellular metabolism is measured as a succession of rates of secretion of hydrogen ion.
At Ϸ16 hr before the experiment, cells were seeded (300,000 cells/chamber) at 75-85% confluency in microphysiometer capsule cups. Capsules were then kept in a CO 2 incubator at 37°. For experimental procedures, the microphysiometer was primed with low buffer media (modified RPMI 1640 medium; Molecular Devices, Menlo Park, CA) for 10 min, sensor chambers were put in place, and cell capsules were placed in the sensor chambers. After calibration of the microphysiometer, cells were allowed to equilibrate in a constant flow of media for 30-60 min to attain a steady base-line of hydrogen ion output. Perfusion was then changed to media containing the test drugs and effects recorded by computer .
Results
Rat nucleus accumbens binding. High affinity reversible binding was observed with the radiolabel sCAL analogue 125 I-AC512 and 125 I-rAmylin. Binding reached steady state by 60-120 min and was displaceable with nonradioactive sCAL and amylin.
125 I-AC512 showed considerably less filter binding and nonspecific binding than 125 I-rAmylin. Over a range of concentrations, 125 I-AC512 yielded much higher specific binding in the rat nucleus accumbens than 125 I-rAmylin. In addition to these improved binding characteristics and in contrast to 125 I-rAmylin, 125 I-AC512 is an antagonist with no observable agonist activity in amylin functional tissue systems, thereby reducing the possible complication of binding effects by G protein coupling.
125
I-AC512 bound with high affinity to membranes prepared from rat nucleus accumbens in a saturable manner (see Table 1 for saturation binding data). Bound 125 I-rAmylin could be displaced with agonists and antagonists. Table 2 shows the chemical structures of the antagonists (AC512, AC66, AC413, hCGRP ) and agonists (rAmylin; human, rat, human, and eel CAL; and rCGRP). The equilibrium dissociation constants of the nonradioactive displacing ligand/receptor complex (K i ) for the displacement of 125 I-amylin are given as negative log values (pK i ) (see Table 3 ). In general, all displacement curves were monophasic with Hill coefficients not significantly different from unity.
Bound 125 I-AC512 also could be displaced with nonradioactive ligands. The data describing the displacement by these ligands are given in Table 4 . In contrast to the simple curves obtained with the antagonists, displacement of 125 I-AC512 with agonists produced complex biphasic curves. The data could be fit with a two-population model; the apparent affinities for the two populations and their relative abundance are given in Table 4 . As seen from these data, the affinity of the agonists varied with the radioligand used. When 125 I-rAmylin was displaced, the agonists produced monophasic curves with high affinities. In contrast, during displacement of 125 I-AC512, biphasic curves with two apparent affinities were obtained.
Human MCF-7 cells. The human breast carcinoma cell line MCF-7 binds 125 I-rAmylin with high affinity; this was confirmed in the current study with membrane from MCF-7 cells. The quantitative data describing this binding activity are given in Table 5 .
125 I-rAmylin bound with affinity similar to that found in the rat nucleus accumbens, but the estimate for the maximal number of 125 I-rAmylin binding sites in 
X ϭ Bolton-Hunter-derivatized lysine.
Bold ϭ amylin-like residues. 
(n ϭ 5) hCGRP 8 -37 8.31 Ϯ 0.37 (Fig. 1, A and B) . Table 6 shows pK i estimates from displacement studies. The affinity of AC512, AC66, and AC413 was comparable to that found for the rat nucleus accumbens. Of note was the 30-fold loss in potency in the MCF-7 cell over the rat nucleus accumbens for hCGRP .
As with rat nucleus accumbens, differences in potencies of displacing ligands were observed with the displacement of bound molpharm.aspetjournals.org curves were obtained for the antagonists, complex displacement curves were obtained for agonists (Fig. 1, C and D) . These curves yielded two apparent affinities and two apparent binding site populations ( Table 7) .
The pK i values in membranes from MCF-7 cells for agonists differed for displacement of 125 I-rAmylin and 125 I-AC512, as observed in the rat nucleus accumbens. A composite experiment of the differences in the displacement curves with rAmylin against 125 I-rAmylin and 125 I-AC512 is shown in Fig. 2 . The levels of initial radioligand binding were comparable, but the location parameters for the displacement curves differed by a factor of nearly 100.
Expression cloning. Transiently transfected COS-7 cells cultured in six-well plates were exposed to 125 I-sCAL or 125 I-AC512 (Ϸ20,000 cpm/well). Both radiolabels were used in separate experiments to maximize the possibility of obtaining a specific amylin-binding protein. A total of 171 pools screened yielded 4 pools exhibiting 125 I-sCAL and 125 I-AC512 binding. From positive pool 77, an additional 20 pools of Ϸ100 clones each were prepared, and 2 subpools were found to be positive on further assay. The positive subpool was subfractionated until a single clone (clone 77) was isolated. A search of the sequence database revealed that the DNA and the deduced amino acid sequence for clone 77 were identical to those for hCTR1 (15) . The only difference between clone 77 and the published sequences was a 78-bp segment missing at the 5Ј untranslated region of clone 77. Insertion of the 78-bp segment created an in-frame ATG by the addition of 26 extra amino acids at the amino terminus of the CTR.
Using the polymerase chain reaction with CTR-specific primers, the three remaining pools were examined and determined to contain the CTR cDNA. Clone 77 cDNA then was used to screen the three positive pools by colony hybridization to isolate additional clones. Sequences of these three clones (clones 40, 134, and 167) revealed different lengths for the 5Ј-and 3Ј-untranslated regions but with no apparent difference in the coding region. Deduced protein sequences were identical to those of hCTR2 isolated from T47D cells (10) . Clone 134 was the longest cDNA among the three and was chosen for further characterization. Comparison of clones 77 and 134 revealed that clone 77 contained a 16-amino acid insert in the first intracellular loop that was absent in clone 134. The differences between the two cDNAs are shown in Fig. 3 (pK i ϭ 10.4). In view of these data, clone 77 was transfected into HEK 293 cells, and a stable cell line expressing hCTR1 was made.
As shown in Table 8 Table 9 . No high affinity binding was observed with agonists in these membranes.
Receptor binding clone 134 (hCTR2): COS-7 cell membranes.
125 I-AC512 bound with high affinity to membranes prepared from COS-7 cells transiently transfected with hCTR2 cDNA. The equilibrium dissociation constant of the AC512/receptor complex was 245 pM (95% CI, 165-370 pM; see Table 10 ). The maximal number of binding sites was 4423 fmol/mg of protein (95% CI, 3603-5242). Binding of somewhat higher affinity was observed with 125 I-sCAL. The K d value was 28.2 pM (95% CI, 7-110 pM). The B max value was 5225 fmol/mg of protein (95% CI, 4235-6214), a value not significantly different from that found for 125 I-AC512 (Table  10) .
The difference between hCTR1 and hCTR2 was that the latter, when transiently transfected into COS-7 cells, also bound 125 I-hCAL in a saturable manner (K d ϭ 417 pM; 95% CI, 269-655 pM). In contrast to the data with 125 I-AC512 and 125 I-sCAL, the B max value for 125 I-hCAL binding was significantly lower (3025 fmol/mg of protein; 95% CI, 1898-4150).
Bound 125 I-AC512 and 125 I-hCAL could be displaced with agonists and antagonists for CTRs. Although the pK i estimates for the displacement of both radioligands with antagonists were uniform (Table 11) , hCAL had a higher estimated affinity for the displacement of 125 I-hCAL (as opposed to 125 I-AC512). Fig. 4 (Table 11 ). 8 -37 6.51 Ϯ 0.12 rCGRP 9.29 Ϯ 0.1 (n ϭ 4) (n ϭ 9)
Receptor binding: HEK 293 cell membranes. Saturable binding of the radioligands was observed in membranes from HEK 293 cells stably transfected with cDNA for hCTR2. The equilibrium dissociation constant of the 125 I-AC512/receptor complex was 209 pM (95% CI, 133-331 pM; see Table   12 ). The maximal number of binding sites (B max ) was considerably larger than that found for COS-7 cell membranes (30, I-rAmylin were fit to a two-site (or two-state) model. A prerequisite to this procedure was a reliable estimate of the total number of binding sites. The (Fig. 6) . It should be noted that although the dissociation kinetics of AC512 and hCAL were reversible, 125 I-sCAL gave essentially irreversible binding. Therefore, displacement of 125 I-sCAL was an unsuitable method for receptor and/or ligand characterization. Specifically, the potency of displacing ligands and the magnitude of nonspecific binding of the pseudoirreversible ligand 125 I-sCAL was de- I-sCAL, the observed IC 50 was significantly lower than if the two ligands were added concomitantly to start the reaction. If the radioligand was added 30 min before the nonradioactive ligand, far less displacement was observed. Similar effects were observed with other nonradioactive ligands (i.e., hCAL). For these reasons, the use of 125 I-sCAL for receptor characterization was not pursued in these studies. However, the quantification of the maximal number of receptors with 125 IsCAL binding is still useful and, this was used to model the saturation binding curves for the agonist radioligands. Fig. 7A (inset) (Fig. 7B) showed a significantly smaller number of high affinity sites (8.8% high affinity sites).
Bound radioligand could be displaced with agonists and antagonists for CTRs. The equilibrium dissociation constants of the nonradioactive displacing ligand/receptor complex (denoted as the K i ) for the displacement of the radioligands are given as negative log values (pK i ) in Table 13 . The pK i estimates for the displacement of all three radioligands with antagonists was uniform (Table 13) ; agonists had a higher estimated affinity for the displacement of 125 I-hCAL and 125 I-rAmylin (as opposed to 125 I-AC512). As was observed in COS-7 membranes, the curve for displacement of 125 I-hCAL was monophasic, whereas that for displacement of 125 I-AC512 was biphasic and shifted to the right. In contrast, there was no significant difference in the potency of AC512 in displacement of these two radioligands. A similar effect, but more pronounced, was seen for amylin displacement of 125 I-rAmylin and 125 I-AC512. Fig. 8 shows the difference in potency demonstrated for amylin in displacement of these two radioligands. Table 15 for pK i values).
Functional responses with hCTR2: microphysiometry. In view of the complex displacement curves seen with some of these ligands and the submaximal saturation kinet- I-sCAL (see Fig. 6 ). The maximal asymptote of this latter curve was used to fit the binding data for 125 I-hCAL to a two-site model. Under these conditions, the data for the specific binding of 125 I-hCAL could be fit to a twosite model in which 24.8% of the sites had a high affinity for 125 I-hCAL. B, Same as for A with 125 I-rAmylin as the radiolabel. The two-site model could be fit for an 8.8% population of high affinity sites for 125 IrAmylin. ics, it was useful to determine which of these ligands produced cellular responses (and thus could be classified as having efficacy with concomitant complex binding behavior). HEK 293 cells transfected with hCTR2 were tested in the cytosensor microphysiometer for the study of functional responses. A HEK 293 cell line expressing a high density of hCTR2 (B max ϭ 28,000 fmol/mg of protein) yielded responses with complex wave forms that changed with hCAL concentration (Fig. 9A) . Due to the rapidly declining phase of the response, dose-response curves could not be obtained in a cumulative manner (i.e., increases in concentration resulted in capricious secondary responses). Interestingly, a clone with a much lower receptor expression level (B max ϭ 65 fmol/mg of protein; 95% CI, 40-96 fmol/mg of protein; K d ϭ 316 pM; 95% CI, 165-650 pM) provided an excellent functional response. In these cells, responses to hCAL were sustained (Fig. 9B ) and yielded cumulative concentration-response curves (Fig. 9C) . AC512 produced concentration-dependent dextral displacement of the hCAL dose-response curve (Fig.  9D ). Schild analysis with the antagonist AC512 provided a regression with a slope not significantly different from unity and a pK B value of 9.1 (95% CI, 9.48-8.7). This was not significantly different from the pK i or pK d value obtained in binding studies (see Tables 12 and 13 ). Receptor-transfected HEK 293 cells responded to a variety of agonists for CTRs and amylin receptors. Fig. 10A shows concentration-response curves to eel, porcine, and rat CAL; hCAL; rCGRP; and rAmylin. No responses to the antagonists AC66, AC413, hCGRP , and AC512 were observed (data not shown). These data are in agreement with those obtained with binding, which showed that the observed affinity of the antagonists did not vary when displacing either the radioligand agonists ( 125 I-hCAL or 125 I-rAmylin) or antagonist ( 125 I-AC512), whereas that of the agonists did. The doseresponse curve to rAmylin was shifted to the right by AC512 (Fig. 10B) . The resulting pA 2 value of 9.1 was not significantly different from the pK B estimated by Schild analysis for blockade of responses to hCAL.
Discussion
These data confirm the results reported previously by Beaumont et al. (6) that described the presence of a high affinity binding site for 125 I-rAmylin in membranes prepared from rat nucleus accumbens. High affinity binding for the radiolabeled amylin receptor antagonist 125 I-AC512 also was confirmed, as reported previously by Watson et al. (9) . The data for MCF-7 cell binding raise the question of the classification of the MCF-7 site as an operational human amylin receptor. This can be done by comparing the binding of ligands to the gene products expressed in the recombinant systems with the characteristics of amylin receptors in the natural systems, namely, the rat nucleus accumbens and MCF-7 cells. There are four unique characteristics of ligand binding to amylin receptors: (i) the high affinity binding for both 125 I-rAmylin and 125 I-AC512, (ii) the complex displacement kinetics between nonradioactive agonist amylin and antagonist radioligand 125 I-AC512, (iii) the characteristically high affinity of rCGRP, and (iv) the similar affinities of the antagonists AC413, AC512, and AC66 in the rat nucleus accumbens and MCF-7 cells. In general, the binding with 125 I-AC512 and 125 I-amylin showed these characteristics and, thus, support the notion that this site can be considered as an amylin receptor. However, the fact that hCGRP 8 -37 clearly distinguishes the rat and human receptor underscores the importance of species differences between the two receptors.
The original intent of this study was to define the human high affinity receptor for amylin in MCF-7 cells. Expression cloning from a library prepared from the human breast carcinoma MCF-7 cell line with a radiolabeled form of the amylin and CAL peptide antagonist AC512 yielded two hCTR isoforms, hCTR1 and hCTR2 (10, (15) (16) (17) . The presence of these receptor isoforms in this cell line has been demonstrated by Albrandt et al. (18) through reverse transcriptionpolymerase chain reaction amplification from reported sequences. The hCTR1, first described in BIN 67 cells (15) , saturably bound 125 I-AC512 and 125 I-sCAL. It is interesting to note that the affinity of 125 I-sCAL is considerably higher in the current membrane study than that reported for wholecell binding [estimated pK i ϭ 10 (16) to 8.0 (19) ]. The higher affinity reported in this study may reflect receptor isomerization due to formation of G protein complexes, a common difference between membrane and whole-cell binding studies; however, it is difficult to interpret estimated affinities with this ligand because the high affinity for the receptor also may reflect the pseudoirreversible kinetics of onset. The unsuitability of 125 I-sCAL in receptor characterization (other than for quantification of receptor number) provided the impetus to characterize the affinities to the agonist and antagonist ligands with 125 I-AC512. The lack of high affinity displacement by rAmylin and the lack of saturable binding for 125 I-rAmylin precluded further exploration of a possible relationship between hCTR1 and amylin in this study; in contrast, the high affinity binding of 125 I-rAmylin to expressed hCTR2 provided a basis for further study. As a prerequisite to a discussion of the data with hCTR2, it is useful to delineate the data in terms of those obtained with agonists and those obtained with antagonists. Ligands with no efficacy are very useful in the process of expression cloning procedure and subsequent identification of products. Unlike those of agonists, the observed binding affinities of antagonists do not vary because of receptor/G protein complexation. The studies with the microphysiometer were helpful in classifying the ligands used in this study; the microphysiometry data with these ligands indicated AC512, AC66, AC413, and hCGRP 8 -37 produced no visible response and, thus, ostensibly qualified as antagonists. By implication, 125 I-AC512 also was considered to be a nonefficacious antagonist. The affinity of this radioligand from saturation binding varied Ͻ2.5-fold among the various expression systems, indicating that the 
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at ASPET Journals on October 28, 2017 molpharm.aspetjournals.org environment of the gene product did not appreciably affect the binding of this ligand. Similarly, the affinity of the antagonist AC413 in displacing the radioligand antagonist 125 I-AC512 was constant over the three expression systems (COS-7, HEK 293, and Ti ni cells). However, some variation for AC66 (Ti ni cells) and hCGRP 8 -37 was observed. In general, the data suggest that the hCTR2 antagonist binding was fairly consistent in the various expression systems used in this study.
A recurrent finding in this work was that agonists were more potent at displacing radiolabeled agonists ( 125 I-hCAL,
125
I-rAmylin) than they were at displacing the radiolabeled antagonist 125 I-AC512. This is consistent with the idea that the agonist radioligands select the high affinity species in a G protein-deprived environment, whereas the antagonist labels a random sampling of bare receptors. The concept of G protein deprivation does not necessarily refer to a stoichiometric deficiency in the ratio of expressed receptors to G proteins but rather to an inability of the expressed receptors to adequately access the existing G proteins due to constraints in the membrane architecture (20) . On displacement with nonradioactive agonist, insufficient G protein exists for complete formation of the high affinity ternary complex; thus, a lower affinity (agonist binding to the receptor not complexed with G protein) is observed. This effect of high affinity selection is made manifest in the significantly different pK i values for agonists when displacing agonist and antagonist radioligands. The idea that there is a G protein insufficiency in some of these systems is supported by the significantly lower B max values for radioactive agonists versus the antagonist 125 I-AC512. The data for 125 I-hCAL indicate that COS-7 cells and baculovirus-expressed Ti ni cells have an equal capability to form the high affinity ternary complex for hCAL (68% and 65% of the receptors, respectively), whereas HEK 293 cells are limited (only 22%). In all cases, however, the maximal number of binding sites measured by agonist saturation binding was much less than the number of receptors as quantified by binding of the antagonist 125 I-AC512. The observance of differences in apparent receptor densities when measured with agonist and antagonist radioligands is known (21) . However, differences in the potencies of agonist ligands when displacing agonist and antagonist radioligands usually produce complex biphasic displacement curves for antagonist displacement. The production of parallel displacement curves with Hill coefficients near unity is more uncommon but also not unknown (22) .
In general, the experimental results can be discussed in terms of two possible hypotheses. The first is that amylin is simply a low efficacy agonist for the CTR. Under these circumstances, the hCTR2 clone is not associated with the amylin binding found in MCF-7 cells (i.e., the amylin receptor gene product was not recovered from these studies). The second is that the CTR functions as the amylin receptor when coupled to certain G proteins in some membranes. These ideas are considered separately.
The first hypothesis to consider is the proposition that amylin is simply a lower efficacy agonist for hCTR2 in these systems and that the amylin effect is not relevant to the amylin binding seen in native MCF-7 cells. In terms of this idea, the two gene products isolated from the MCF-7 cell library are not related to the high affinity amylin binding found in the MCF-7 cells. The small quantity of high affinity binding of 125 I-rAmylin found in COS-7 and HEK 293 cells and the high affinity selection effects would then represent a separate activity of rAmylin for the hCTR2. In terms of this hypothesis, a human amylin receptor awaits discovery in the MCF-7 cell library. This hypothesis is based on the interaction between receptors and G proteins. The ternary complex models for seven-transmembrane receptors incorporate an intrinsic affinity constant between the activated receptor and G proteins (23) (24) (25) (26) . Under these circumstances, there is a stoichiometric relationship between the receptor and G protein that depends on this affinity constant and the relative amounts of receptor and G protein. In G protein-deprived systems, the amount of activated receptor dictates the amount of complex of receptor and G protein. Thus, a low efficacy partial agonist may produce a lower amount of activated receptor than a high efficacy agonist with a subsequently lower quantity of high affinity agonist complex. These effects have been observed directly with cholinergic agonists (27, 28 ) (see Ref. 29 for a discussion). The fact that hCAL produces 24.8% high affinity complex in HEK 293 cells while amylin produces only 8% is consistent with the idea that amylin produces less of the activated state than hCAL (i.e., it simply is a lower efficacy agonist for the CTR).
A second hypothesis describes a system in which hCTR2 couples to one G protein for CAL function and another for amylin function. This latter G protein may not be present in all cellular systems, thus conferring cellular selectivity for amylin effect. There is a considerable body of evidence to show that CTRs in general couple to a variety of G proteins [i.e., G s , G i , and G q ; see Horne et al. (30) for a review]. In addition, the promiscuous coupling of this receptor has been shown to alter with cell cycle as well (31) . In the current series of experiments, there are two lines of evidence consistent with a hypotheses of separate G protein coupling for hCAL and rAmylin. The first is the disparate formation of high affinity ternary complexes formed by hCAL and rAmylin as measured by radioligand saturation binding in all of these systems (i.e., 24.8% for 125 I-hCAL versus 8% for 125 IrAmylin). In terms of this hypothesis, the different B max values for the two agonists may reflect different stoichiometries of the different G proteins. However, this is not definitive because this also is consistent with amylin simply being a lower efficacy agonist for hCTR2 (see above).
The main support for the second hypothesis is related to the extremely selective affinity of rAmylin and rCGRP for displacement of 125 I-rAmylin and the considerably lower potency in displacing 125 I-hCal (i.e., they are of low activity at CTRs). This suggests that the CTR changes character when bound to 125 I-amylin. In view of the high degree of high affinity selection for 125 I-rAmylin displacement over displacement of 125 I-AC512 observed for amylin in MCF-7 cells (the source of the transfected receptor hCTR2) and the fact that the same is not true for hCAL suggest that the MCF-7 cell possesses a G protein or other factor to confer high rAmylin binding in that system and that this factor is lost on transfection into COS-7, HEK 293, and Ti ni cells. The factor need not be a specific G protein; it could be an auxiliary player in the receptor coupling process. For example, protein factors that tightly couple adenosine receptors (32) and ␣ 2A/ D-adrenergic receptors (33) have been described recently. Removal of these from host membranes results in loss of high affinity binding of agonists to receptors.
In conclusion, these data describe receptor binding characteristics of two hCTR isoforms in various expression systems for CAL and amylin ligands. The provocative association of the hCTR2 with high affinity amylin binding requires further study and may have implications for the understanding of selective cellular signaling of hormones and the use of gene products to attain signaling diversity. In view of the similar affinities of all of these agonist and antagonist radioligands for amylin binding in MCF-7 cells and that found in these expression studies with hCTR2, it could be inferred that these effects are mediated either by one receptor coupling to various membrane components or by separate but similar receptors.
